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Background: As lithium treatment might be effective in reducing the risk of deliberate self-harm (DSH) in adult
patients with unipolar affective disorders, we designed a pragmatic randomised trial to assess its efficacy in more
than 200 patients with treatment-resistant depression. However, we randomised 56 patients only. The aim of this
report is therefore twofold: first, to disseminate the results of this underpowered study which may be incorporated
into future meta-analytical reviews; second, to analyse some critical aspects of the study which might explain failure
to reach the target sample size.
Methods: We carried out a randomised, parallel group, assessor-blinded superiority clinical trial. Adults with a
diagnosis of major depression, an episode of DSH in the previous 12 months and inadequate response to at least
two antidepressants given sequentially at an adequate dose for an adequate time for the current depressive episode
were allocated to add lithium to usual care (intervention arm) versus usual care alone (control arm). Suicide completion
and acts of DSH during the 12 months of follow-up constituted the composite primary outcome.
Results: Of 58 patients screened for inclusion, 29 were allocated to lithium plus usual care and 27 were assigned
to usual care without lithium. Six patients in the lithium plus usual care group and seven in the usual care group
committed acts of DSH during the follow-up phase. The survival probability did not differ between the two treatment
arms (Chi2 = 0.17, p =0.676). With regard to changes in the severity of depressive symptomatology from baseline to
endpoint, no significant differences were detected.
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Conclusions: The present study failed to achieve the minimum sample size needed to detect a clinically meaningful
difference between the two treatment arms. Consequently, the finding that lithium, in addition to usual care, did not
exert a positive effect in terms of reduction of DSH after 12 months of follow-up is likely due to the lack of sufficient
statistical power to detect a difference, if a difference existed. The dissemination of the results of this underpowered
study will inform future meta-analytical reviews on lithium and suicide-related outcomes.
Trial registration: ClinicalTrials.gov identifier: NCT00927550
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There is some evidence that lithium treatment might be
effective in reducing the risk of suicide-related outcomes
in patients with treatment-resistant depression (TRD)
[1-3]. A recent systematic review of 48 randomized trials
(6674 participants), which investigated the effect of lithium
on the risk of suicide and deliberate self-harm (DSH) in
patients with mood disorders, found that lithium was more
effective than placebo in reducing the number of suicides
(odds ratio (OR) 0.13, 95% confidence interval (CI) 0.03 to
0.66) and deaths from any cause (OR 0.38, 95% CI 0.15
to 0.95) [4]. However, no clear benefits were observed
for lithium compared with placebo in preventing delib-
erate self-harm (OR 0.60, 95% CI 0.27 to 1.32) [4]. In
unipolar depression, lithium was associated with a
reduced risk of suicide (OR 0.36, 95% CI 0.13 to 0.98),
although the confidence interval around the point esti-
mate ranged from substantial beneficial effect to almost
no effect. Of note, the included trials were not primarily
designed to measure this outcome, and heterogeneous
patient populations were enrolled. Additionally, while
some trials included acutely depressed patients, euthymic
cases were enrolled in other studies.
On these grounds, we designed a pragmatic rando-
mised trial to assess whether adding lithium to usual
care is an effective treatment strategy to reduce the risk
of suicidal behaviour in long term treatment of people
with TRD and previous history of DSH. As reported in
the study protocol [5], we initially planned to include
more than 200 participants, but we managed to random-
ise 56 patients only. The aim of this report is therefore
twofold: first, to disseminate the results of this under-
powered study which may be incorporated into future
meta-analytical reviews; second, to analyse some critical
aspects of the study which might explain failure to reach
the target sample size.
Methods
Study design
The study was funded by the Italian Medicine Agency
and received ethical approval in each participating site.
The Ethics Committee in Verona (coordinating centre)
approved the study on May 6th 2009 (Study code:LAST-RD - FARM77Z3BL5.101-03-2009; Approval number
1675). A detailed description of the study methods has
already been published [5]. Patients with a diagnosis of
TRD and history of DSH were randomly allocated to (i)
add lithium to usual care or (ii) usual care without lith-
ium. Patients were randomly assigned to one of the two
treatment groups with an equal probability of assign-
ment to each treatment (allocation ratio 1:1). A centralised
randomisation procedure was employed to preserve allo-
cation concealment and stratified by presence or absence
of Axis II diagnosis. In order to resemble ordinary prac-
tice, patients and clinicians were not blind to treatments
provided during the trial. However, to limit the potential
for ascertainment bias, an independent adjudicating com-
mittee, blind to treatment allocation, validated the events
that constituted the primary outcome. Patients were
assessed at baseline and then every month after random
allocation until the completion of the 12-month follow-
up, using an ad hoc and structured form. Acts of DSH and
suicide during the 12 months of follow-up constituted the
composite primary outcome. A sample size calculation [5]
revealed that 210 patients would have 80% power to show
a clinically significant advantage associated with lithium
treatment. All phases of the trial were recorded following
the CONSORT statement [6,7].
Inclusion criteria
The following inclusion criteria were adopted: (a) diag-
nosis of unipolar major depression (clinical diagnosis,
guided by DSM-IV criteria); (b) an episode of DSH in
the previous 12 months; (c) inadequate response to
at least two antidepressants given sequentially at an
adequate dose for an adequate time for the current
depressive episode; (d) uncertainty about which treat-
ment arm would be best for the participant; (e) age 18
or above; (f ) to sign written informed consent.
Exclusion criteria
The following exclusion criteria were adopted: (a) a primary
diagnosis of any concurrent Axis I disorder (according to
DSM-IV criteria) other than major depression (by contrast,
any concurrent DSM-IV Axis II disorder was not an exclu-
sion criterion); (b) previous exposure to lithium associated
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conditions contraindicating lithium (i.e., thyroid or kidney
disease/abnormalities); (d) pregnant/lactating women and
women of childbearing potential not practicing a reliable
method of contraception.
Assessments
The following information was collected at baseline:
socio-demographic and clinical characteristics, diagnosis
according to the Mini Neuropsychiatry Interview (MINI)
[8], severity of illness according to the Quick Inventory
Depression Scale (QIDS) [9], a self-rated instruments
that has been shown to have good psychometric proper-
ties [10]. Follow-up data were obtained monthly after
random allocation using an electronic form, as follows:
any death or DSH, lithium oral dose and plasma level
(if applicable), and QIDS scores. Patients allocated to
lithium were administered an oral starting dose ranging
between 150 and 300 milligrams (according to clinical
judgement). Suggested final oral dose had to achieve
plasma levels from 0.4 to 1.0 mmol/L. Clinicians were
free of increasing or decreasing the dose according to
clinical status and circumstances.
Statistical analysis
All randomized subjects with at least one post-baseline
assessment were considered in the analysis of primary
and secondary outcomes. Patients with missing values
and lost during follow-up contributed to the analysis of
the primary and secondary outcomes only for the time
during which data are available (censoring). Missing
values in depressive symptom ratings were imputed
using the last observation carried forward (LOCF)
approach: depressive ratings were carried forward from
the last available assessment to the 12-month follow up
assessment. Additionally, patients in each arm were
always analysed according to the corresponding treat-
ment group’s allocation at baseline.
Kaplan-Meier estimates for the time from randomised
treatment assignment until the first event that consti-
tutes the primary outcome were plotted to compare the
treatment’s effect, and log-rank test was performed to
test for differences.
Change in severity of depressive symptoms from base-
line to 12 months was compared between the two groups
of treatment through appropriate statistical methods for
repeated measurements (paired t-test or McNemar non
parametric test according to the variables distribution).
Results
Socio-demographic and clinical characteristics
Of 58 patients screened for inclusion, a total of 56 were
enrolled in the study and randomly assigned to treat-
ment (Figure 1); 29 subjects were allocated to lithiumplus usual care and 27 were assigned to usual care
without lithium. Two patients withdrew consent and
left the study immediately after random allocation. Five
additional patients withdrew from the study during
follow-up (Figure 1). Table 1 shows the baseline socio-
demographic and clinical characteristics of the study
sample. The majority of study participants were female,
married, with high level of education; the mean age was
46 and 47 years in the lithium and usual care group,
respectively.
The majority of patients were admitted to a psychiatric
facility in the previous 12 months, one third had a concur-
rent diagnosis of personality disorder, and only a minority
suffered from alcohol or drug use problems. A proportion
of 45% in the lithium group and 40% in the usual care
group had two or more acts of DSH recorded in the previ-
ous 12 months. Only a minority of cases had already been
exposed to lithium in the past (Table 1).
Table 2 presents the use of antidepressants, antipsy-
chotics, benzodiazepines and mood stabilizers during
the study period. Patients allocated to lithium used less
often antipsychotics and mood stabilizers, although
differences were not statistically significant.
Lithium efficacy
Lithium was administered during the study at a mean
dose of 444 mg (Standard Deviation (SD) =304), with
a mean blood level of 0.57 mEq/L (SD =0.24). A total of
11 patients allocated to lithium experienced adverse
effects that the treating psychiatrist attributed to lithium.
Six patients in the lithium plus usual care group and
seven in the usual care group committed acts of DSH
during the follow-up phase; one of the six patients in the
lithium plus usual care group died by suicide versus
none of the seven patients in the usual care group.
Figure 2 shows the Kaplan-Meier survival curve for the
primary outcome. The survival probability did not differ
between the two treatment arms (Chi2 = 0.17, p =0.676).
The survival probability at 12 month was 75% and 65%
in the lithium and standard therapy group, respectively.
With regard to changes in the severity of depressive
symptomatology from baseline to endpoint, no signifi-
cant differences were detected (Table 3).
Discussion
The present study failed to achieve the minimum sample
size needed to detect a clinically meaningful difference
between the two treatment arms. Consequently, the find-
ing that lithium, in addition to usual care, did not exert
a positive effect in terms of reduction of DSH after
12 months of follow-up is likely due to the lack of suffi-
cient statistical power to detect a difference, if a difference
existed (type-II error). Considering that most individual
studies carried out on this topic suffer from low statistical
Patients assessed for 
eligibility (n=58) 
2 excluded patients: 
- not meeting inclusion criteria 
Patients (n=29)
Randomised (n=56)
Lithium + usual care (n=29) Usual care (n=27) 
Patients (n=25)
2 patients left 
the study after 
randomisation 
BASELINE 
2 patients did not provide 
available data for the 
secondary outcome 
analysis (n=27) 
Included in the primary 
outcome analysis (n=29) 
Included in the primary 
outcome analysis (n=25) 
12 MONTH 
FOLLOW-
UP 
3 patients did not provide 
available data for the 
secondary outcome 
analysis (n=22) 
Figure 1 Study flow-diagram.
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Table 1 Distribution of patients’ socio-demographic and clinical characteristics by allocated treatment
Lithium + Usual care (n = 29) Usual care (n = 25) p
N %/mean n %/mean
Females (%) 16 55 18 72 0.202
Age (years), mean (SD) 29 46 (12.3) 25 47 (9.4) 0.853
Education (%) 0.951
Primary school certificate 13 45 11 44
High school education/degree 16 55 14 56
Occupational status (%) 0.342
Employed 15 52 8 32
Unemployed 6 21 7 28
Other 8 28 10 40
Marital status 0.944
Unmarried 8 28 6 24
Married 15 52 14 56
Divorced/Widowed 6 21 5 20
Psychiatric admissions in the previous 12 months (%)
0 10 34 7 28
1 11 38 9 36 0.781
≥2 8 28 9 36
Personality disorders (%) 10 34 7 28 0.609
Current alcohol/drug abuse 0 0 2 8 0.210
History of alcohol abuse 4 14 8 32 0.188
Acts of self-harm in the previous 12 months (%) 0.721
1 16 55 15 60
≥2 13 45 10 40
Physical illness (%) 12 41 5 20 0.092
Past use of antidepressants (number), mean (SD) 29 3 (1.9) 25 3 (1.9) 0.470
Past use of lithium (%) 4 14 3 12 1.000
Legend: SD = Standard deviation.
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clinical trial data, by pooling together all available stud-
ies, will have a chance of detecting clinically meaningful
differences. It is therefore of paramount relevance that
the results of all randomised evidence is published and
available to researchers, irrespective of statistical power
or study outcome.
A second relevant aspect is to analyse the critical fea-
tures of the study which might explain failure to reachTable 2 Use of antidepressants, antipsychotics, benzodiazepi
Lithium + Usual care (n = 29)
N %
Antidepressants 26 96
Antipsychotics 16 59
Benzodiazepines 23 85
Mood stabilizers 10 37the target sample size, in order to assist investigators
designing future studies on this topic. First, this study
was aimed at providing a scientific answer to a clinically
relevant question enrolling real-world patients. We were
able to build a research network of mental health profes-
sionals who accepted the idea of using their everyday
clinical practice to produce scientific knowledge. This
research infrastructure proved to work efficiently in a
previous experimental study which was conducted andnes and mood stabilizers during the study period
Usual care (n = 25) p
n %
23 100 1.000
16 70 0.449
20 87 0.100
10 43 0.643
Figure 2 Kaplan-Meier curve showing the survival probability in patients allocated to lithium plus usual care (n = 29) versus usual care
(n = 27). Acts of deliberate self-harm were the outcome measure.
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of more than 50 Italian community psychiatric services
that were initially interested in the study, only 22 were
able to contribute and randomised at least one patient.
Reasons for not contributing included lack of staff that
might follow the process of ethics committee approval
or, for some services where the protocol was approved,
lack of dedicated personnel to actually recruit patients.
The availability of study funding provided by the Italian
Medicine Agency failed to overcome these practical issues,
as funding was allocated to each service too late, due to a
very long and time-consuming administrative process.
Second, despite an attempt was made to define broad
and clinically-sound entry criteria, very few eligible cases
were identified (Figure 1). The main issue was that most
patients seen in clinical practice with a recent history of
DSH and a depressive episode did not have a diagnosis
of unipolar depression but, rather, of bipolar depression.
In our study, however, a diagnosis of bipolar depression
was an exclusion criterion, as data have already shown a
beneficial effect of lithium in these patients. In addition,
in recent years there is a trend of interpreting patients
with affective features and acts of DSH as having bipolar
disorder more than unipolar depression, so that evenTable 3 Mean change in depressive symptomatology from ba
Lithium + Usual ca
QIDS at baseline, mean (SD) 16.81 (4.05)
Mean change (SD) [confidence interval] −7 (8.2) [−10.2, −3.8
Legend: SD = Standard deviation.patients with a history of depressive episodes and some
acts of DSH were considered cases belonging to the
so-called bipolar spectrum, being therefore ineligible for
the study [14].
Third, some patients were not considered eligible be-
cause the treating psychiatrists deemed as not clinically
reasonable the use of lithium. The main concern was the
use of a medicine with a narrow therapeutic/toxic ratio,
which requires regular serum level tests. Lithium overdose
may cause nausea, emesis, diarrhea, asthenia, ataxia,
confusion, lethargy, polyuria, seizures and coma. Other
toxic effects of lithium include coarse tremor, muscle
twitching, convulsions and renal failure. People who
survive a poisoning episode may develop persistent
neurotoxicity [15]. Clearly, in patients selected on the
basis of a recent episode of self-harm, doctors were
reluctant to prescribe a potentially dangerous mean
which could be used for committing other acts of DSH.
The counterargument of the evidence base suggesting a
potential beneficial rather than harmful effect of lithium
in the long-term was not convincing when individual
cases were approached.
Fourth, in patients with TRD lithium is not the only
therapeutic options, as second-generation antipsychoticsseline to follow-up
re (n = 27) Usual care (n = 22) P
20.05 (2.89)
0] −6.1 (5.7) [−8.62, −3.56] 0.951
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and used in clinical practice [16]. A recent systematic
review identified 14 randomised trials of aripiprazole,
olanzapine/fluoxetine combination, quetiapine, and ris-
peridone [17]. It found that SGAs for the adjunctive
treatment of depression are efficacious in reducing
observer-rated depressive symptoms, although the benefit
is small to moderate and short-term. Quetiapine in several
countries, including Italy, has a licensed indication for the
pharmacological treatment of TRD. On clinical grounds,
therefore, the addition of one of the SGAs may be consid-
ered more suitable and less dangerous option than the
addition of lithium. SGAs, additionally, do not require that
strict monitoring that must be followed with lithium treat-
ment. These considerations may have prevented doctors
to include several potentially eligible patients into the trial.
Conclusions
The dissemination of the results of this underpowered
study may inform future meta-analytical reviews on
lithium and suicide-related outcomes. As the problem of
missing trials is one of the greatest ethical and practical
problems facing medicine today, it is considered impera-
tive that all trials are registered and their results fully
published [18].
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